Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity

Condition(s) targeted: Binge Eating Disorder; Obesity

Intervention: Lamotrigine (Drug); placebo (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: University of Cincinnati

Official(s) and/or principal investigator(s):
Susan L. McElroy, MD, Principal Investigator, Affiliation: University of Cincinnati

Overall contact:
Susan L. McElroy, MD, Phone: 513-558-1133, Email: susan.mcelroy@uc.edu

This research study is to evaluate the effectiveness, tolerability, and safety of lamotrigine therapy in the treatment of binge eating disorder associated with obesity.

Lamotrigine has been approved by the Food and Drug Administration for the treatment of bipolar disorder, but has not been approved for use in the treatment of binge eating disorder with obesity.

Official title: Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Single Group Assignment

Primary outcome: The specific aims of this study are to examine the efficacy and safety of lamotrigine compared with placebo in outpatients with binge eating disorder associated with obesity.

Detailed description: This is a 17-week, parallel group, placebo-controlled, randomized, double-blind, flexible-dose, single-center study. It begins with a 1 to 2 week screening period during which there will be washout of other medications and evaluation of protocol-specified criteria. The screening period will consist of at least two visits, which will include the initial screening visit and the baseline (week 1) visit. The treatment period follows the screening period and will last 16 weeks. Once a subject enters the treatment phase (after randomization) the dosage of study medication will be 25 mg/qHS (or one placebo tablet at night) for 14 days. On day 14 (visit 2 or the beginning of week 3), the dosage will be increased, as tolerated, to 25 mg b. i.d. On day 28 (visit 4 or in the beginning of week 5), the dosage will be increased, as tolerated, to 50 mg b. i.d. On day 35 (visit 5 or the beginning of week 6), the dosage will be increased, as tolerated, to 100 mg b. i.d. The dosage may be decreased at any time because of side effects. If the patient prefers, he or she may take all of his or her daily dose of medication in the morning or evening. If no response or an inadequate response (< 50% reduction in binge eating episodes compared with baseline) is evident by week 6 (visit 6), study medication may be increased to 150 mg b. i.d. If no response or an inadequate response is evident by week 8 (visit 7), study medication may be increased to 200 mg b. i.d. During weeks 12 through 16 (maintenance period) the dosage will not be changed unless a medical reason (e. g., adverse effect) requires such a change. The minimum dosage allowed will be 50 mg/day and the maximum dosage allowed will be 400 mg/day. The 16-week treatment period will be followed by medication discontinuation and evaluation 1 week after medication discontinuation (week 17). Efficacy and safety evaluations will be done at each visit starting with the baseline visit through week 17 (baseline, weeks 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16).

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients will meet DSM-IV-TR criteria for BED for at least the last 6 months,

determined by the Structured Clinical Interview for DSM-IV-TR (SCID) (61) and supported by the Eating Disorder Examination (EDE) (62). These criteria are as follows:

- Recurrent episodes of binge eating. An episode of binge eating is characterized

by both of the following:

- eating, in discrete period of time (e. g., within any two hour period), an

amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances

- a sense of lack of control over eating during the episode (e. g., a feeling

that one cannot stop eating or control what or how much one is eating)

- The binge eating episodes are associated with at least three of the

following:

- eating much more rapidly than normal

- eating until uncomfortably full

- eating large amounts of food when not feeling physically hungry

- eating alone because of being embarrassed by how much one is eating

- feeling disgusted with oneself, depressed, or feeling very guilty after

overeating

- Marked distress regarding binge eating.

- The binge eating occurs, on average, at least two days a week for six months.

- Does not occur exclusively during the course of bulimia nervosa and anorexia

nervosa.

- Obesity, defined by body mass index > 30 kg/m2.

- Men or women, between the ages of 18 and 65.

Exclusion Criteria:

- Have current body mass index < 30 kg/m2.

- Women who are pregnant or lactating and women of childbearing potential who are not

taking adequate contraceptive measures. (All women of childbearing potential will have a negative pregnancy test before entering the study.)

- Subjects who are displaying clinically significant suicidality or homicidality.

- Subjects who are displaying a current clinically unstable depressive or bipolar

disorder, defined as a Montgomery Asberg Depression Rating Scale (MADRS) (63) > 24 or a Young Mania Rating Scale (YMRS) (64) > 8.

- A current or recent (within 6 months of the start of study medication) DSM-IV-TR

diagnosis of substance abuse or dependence.

- A lifetime history of a DSM-IV-TR psychotic disorder or dementia.

- History of a personality disorder (e. g., schizotypal, borderline, or antisocial) which

might interfere with assessment or compliance with study procedures.

- Clinically unstable medical disease, including cardiovascular, hepatic, renal,

gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, assessment, or treatment of binge eating disorder. Patients should be biochemically euthyroid prior to entering the study.

- History of seizures, including febrile seizures in childhood.

- Subjects requiring treatment with any drug which might interact adversely with or

obscure the action of the study medication (e. g., stimulants, sympathomimetics, antidepressants, carbonic anhydrase inhibitors, anti-obesity drugs).

- Subjects who have received psychoactive medication (other than zaleplon [Sonata] or

zolpidem [Ambien] - - as needed for restlessness/insomnia) within one week prior to

randomization.

- Subjects who have begun and/or are receiving formal psychotherapy (cognitive

behavioral therapy, interpersonal therapy, or dietary behavioral therapy) for BED or weight loss within the past 3 months.

- Subjects previously enrolled in this study or have previously been treated with

lamotrigine.

- Subjects who have received an experimental drug or used an experimental device within

30 days.

Susan L. McElroy, MD, Phone: 513-558-1133, Email: susan.mcelroy@uc.edu

University of Cincinnati Medical Center, Cincinnati, Ohio 45267-0559, United States; Recruiting
Susan L. McElroy, MD, Principal Investigator

Starting date: March 2006
Ending date: December 2009
Last updated: November 13, 2008